Philip J. Buffington, MD, chief medical officer at The Urology Group, recently spoke at the Large Urology Group Practice Association’s (LUGPA) annual conference about Firmagon, a prostate cancer treatment drug.
Philip J. Buffington, MD, chief medical officer at The Urology Group, recently spoke at the Large Urology Group Practice Association’s (LUGPA) annual conference about Firmagon, a prostate cancer treatment drug.
